MRA Advisory Group Sells 29 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

MRA Advisory Group cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 438 shares of the medical research company’s stock after selling 29 shares during the quarter. MRA Advisory Group’s holdings in Thermo Fisher Scientific were worth $242,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of TMO. Koss Olinger Consulting LLC purchased a new position in Thermo Fisher Scientific in the second quarter worth $294,000. Caprock Group LLC grew its position in shares of Thermo Fisher Scientific by 39.0% in the second quarter. Caprock Group LLC now owns 9,695 shares of the medical research company’s stock valued at $5,366,000 after purchasing an additional 2,719 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $56,462,000. Umpqua Bank increased its position in shares of Thermo Fisher Scientific by 7.6% in the second quarter. Umpqua Bank now owns 4,441 shares of the medical research company’s stock worth $2,456,000 after purchasing an additional 315 shares during the last quarter. Finally, Cobblestone Capital Advisors LLC NY raised its position in Thermo Fisher Scientific by 3.6% during the second quarter. Cobblestone Capital Advisors LLC NY now owns 683 shares of the medical research company’s stock valued at $378,000 after purchasing an additional 24 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. TD Cowen raised their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Wells Fargo & Company began coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 target price for the company. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $630.41.

Thermo Fisher Scientific Stock Up 0.7 %

Shares of NYSE TMO opened at $611.33 on Friday. The firm has a fifty day simple moving average of $584.07 and a two-hundred day simple moving average of $578.20. The firm has a market capitalization of $233.35 billion, a PE ratio of 39.21, a price-to-earnings-growth ratio of 2.85 and a beta of 0.78. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same period last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific’s quarterly revenue was down 1.4% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the sale, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.